Rovalpituzumab 生物类似药, 人 DLL3 单克隆抗体产品图
文献支持

Rovalpituzumab 生物类似药, 人 DLL3 单

克隆抗体
收藏
  • 询价
  • Promab
  • 美国
  • PMB-B00063
  • 2025年07月12日
  • Human DLL3
  • 66
  • Human
avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 免疫原

      CHO cells

    • 亚型

      Human DLL3

    • 形态

      Flow cytometry, animal model study

    • 保存条件

      Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.

    • 克隆性

      Human DLL3

    • 标记物

      Flow cytometry, animal model study

    • 适应物种

      Human

    • 保质期

      CHO cells

    • 抗原来源

      Human DLL3

    • 目录编号

      Flow cytometry, animal model study

    • 级别

      77

    • 库存

      10

    • 供应商

      艾美捷科技

    • 宿主

      66

    • 应用范围

      Human DLL3

    • 浓度

      55

    • 靶点

      CHO cells

    • 抗体英文名

      Rovalpituzumab Biosimilar, Human DLL3 Monoclonal Antibody

    • 抗体名

      Rovalpituzumab 生物类似药, 人 DLL3 单克隆抗体

    Rovalpituzumab 生物类似药, 人 DLL3 单克隆抗体,Rovalpituzumab Biosimilar, Human DLL3 Monoclonal Antibody,Rovalpituzumab Biosimilar, Human DLL3 Monoclonal Antibody,Rovalpituzumab 生物类似药, 人 DLL3 单克隆抗体

    产品名称:-In vivo级抗体试剂

    产品货号:PMB-B00063

    产品规格:询价/1mg/5mg/20mg

    产品细节图片1

    应用类型:Flow cytometry, animal model study

    产品细节图片2

    What is rovalpituzumab biosimilar research grade? Rovalpituzumab is a humanized IgG1-kappa monoclonal antibody against the human Delta-like 3 protein (DLL3), which is an atypical Notch ligand that has been implicated in regulation of cell development and cell fate decisions, and is a downstream target of achaetescute homolog-1 (ASCL1), suggesting its role in neuroendocrine tumorigenesis. DLL3 is expressed in more than 80% of patients with small-cell lung cancer (SCLC) and other neuroendocrine tumors, but has little to no expression in normal tissues or non-neuroendocrine tumor types. DLL3 expression appears to be stable over time in SCLC tumors pre- and post-chemotherapy. Although DLL3 is mostly found within the Golgi apparatus under physiological conditions, it may reach the cell surface in case of overexpression and lead to Notch inhibition in cis. Rovalpituzumab tesirine (Rova-T) is a first-in-class antibody–drug conjugate (ADC) against DLL3, and composed of SC16, a humanized IgG1 antibody against DLL3, conjugated to the cytotoxic pyrrolobenzodiazepine (PBD) dimer D6.5 (SC-DR002) via a protease-cleavable linker. Rova-T selectively binds to DLL3 on target-expressing cells, is internalized, and upon proteolytic cleavage releases the toxin. PBD dimers then bind to the DNA minor groove where they form covalent adducts causing stalling of the replication forks, cell-cycle arrest at the G2–M boundary, and apoptosis. Rovalpituzumab biosimilar uses the same protein sequences as the therapeutic antibody rovalpituzumab.

    产品细节图片3

    -In vivo级抗体试剂Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.

    点击:-In vivo级抗体试剂更多Promab产品信息价格,货期,产品说明,百度搜“艾美捷科技”进入官网网站,查看具体产品且快速下单。

    Promab

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献
    Human
    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    询价
    武汉佰瑞得生物技术有限公司
    2025年07月12日询价
    询价
    亚科因(武汉)生物技术有限公司
    2026年05月29日询价
    ¥55
    艾美捷科技有限公司
    2025年11月12日询价
    询价
    维百奥(北京)生物科技有限公司
    2026年05月28日询价
    ¥160
    北京索莱宝科技有限公司
    2025年09月23日询价
    文献支持
    Rovalpituzumab 生物类似药, 人 DLL3 单克隆抗体
    询价